Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Ruxrungtham

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
International Journal of STD & AIDS|March 24, 2011
Genital shedding of HIV after scheduled treatment interruptionJ Ananworanich, S J Kerr, P Vernazza, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 21, 2013
The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)P Cahn, K Ruxrungtham, B Gazzard, et al.
Clinical Pharmacology and Therapeutics|January 2, 2009
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adultsA Avihingsanon, J van der Lugt, S J Kerr, et al.
AIDS (London, England)|August 10, 2000
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patientsK Ruxrungtham, E D Kroon, C Ungsedhapand, et al.
Journal of the Medical Association of Thailand = Chotmaihet Thangphaet|September 1, 2001
Short course zidovudine maternal treatment in HIV-1 vertical transmission: randomized controlled multicenter trialS Limpongsanurak, P Thaithumyanon, S Chaithongwongwatthana, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2001
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonatesC Rongkavilit, P Thaithumyanon, T Chuenyam, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 19, 2001
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patientsC Ungsedhapand, E D Kroon, S Suwanagool, et al.
HIV Medicine|September 18, 2008
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227K Ruxrungtham, R J Pedro, G H Latiff, et al.
AIDS (London, England)|August 10, 2000
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research CollaborationE D Kroon, C Ungsedhapand, K Ruxrungtham, et al.
Allergy|March 29, 2016
The minor house dust mite allergen Der p 13 is a fatty acid-binding protein and an activator of a TLR2-mediated innate immune responseP Satitsuksanoa, M Kennedy, D Gilis, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
International Journal of STD & AIDS|March 24, 2011
Genital shedding of HIV after scheduled treatment interruptionJ Ananworanich, S J Kerr, P Vernazza, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 21, 2013
The immunomodulatory nutritional intervention NR100157 reduced CD4+ T-cell decline and immune activation: a 1-year multicenter randomized controlled double-blind trial in HIV-infected persons not receiving antiretroviral therapy (The BITE Study)P Cahn, K Ruxrungtham, B Gazzard, et al.
Clinical Pharmacology and Therapeutics|January 2, 2009
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adultsA Avihingsanon, J van der Lugt, S J Kerr, et al.
AIDS (London, England)|August 10, 2000
A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patientsK Ruxrungtham, E D Kroon, C Ungsedhapand, et al.
Journal of the Medical Association of Thailand = Chotmaihet Thangphaet|September 1, 2001
Short course zidovudine maternal treatment in HIV-1 vertical transmission: randomized controlled multicenter trialS Limpongsanurak, P Thaithumyanon, S Chaithongwongwatthana, et al.
Antimicrobial Agents and Chemotherapy|November 16, 2001
Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonatesC Rongkavilit, P Thaithumyanon, T Chuenyam, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 19, 2001
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patientsC Ungsedhapand, E D Kroon, S Suwanagool, et al.
HIV Medicine|September 18, 2008
Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227K Ruxrungtham, R J Pedro, G H Latiff, et al.
AIDS (London, England)|August 10, 2000
A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research CollaborationE D Kroon, C Ungsedhapand, K Ruxrungtham, et al.
Allergy|March 29, 2016
The minor house dust mite allergen Der p 13 is a fatty acid-binding protein and an activator of a TLR2-mediated innate immune responseP Satitsuksanoa, M Kennedy, D Gilis, et al.
Pageof 5